reduce insulin dose when starting glp-1 receptor agonist Evolution of GLP‐1 Agonists for Diabetes Treatment GLP-1 Drugs and Type 1

Since most glucose-dependent insulinotropic polypeptide (GIP) receptor: glucagon-like peptide- 1 receptor (GLP- 1) receptor: glucagon receptor triagonists compete in efficacy with bariatric surgery, the success of these agents in preclinical models and clinical trials suggests a bright future for multi-agonists in the treatment of metabolic diseases

L.MurphyK

Tirzepatide's dual-agonist mechanism provides superior glycemic control with HbA1c reductions of 1.5-2.4%, compared to 1.2-1.8% for single-agonist alternatives

[DOI] [PMC free article] [PubMed] [Google Scholar] 69.Allison DB, Gadde KM, Garvey WT, et al

Gestational diabetes mellitus: who requires insulin therapy

Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA